As part of our series focussing on available medicines in Australia, we have added a product review of use of ofatumumab for the treatment of relapsing forms of multiple sclerosis.
This review discusses indications and dosage, contraindications and a series of clinical studies featuring ofatumumab use. It also provides commentary from Professor Tomas Kalincik, the director of the Neuroimmunology Centre at the Royal Melbourne Hospital.
Please login below to download this issue (PDF)